Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market - GBI Research Reports

Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market

Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market - GBI Research Reports
Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market
Published Oct 15, 2011
154 pages — Published Oct 15, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market, which provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Researchs analysis shows that the global cancer vaccines market for cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma was valued at $1,657m in 2010. The market is expected to witness a Compound Annual Growth Rate (CAGR) of 21% for the forecast period (2010-2017) and will reach $6.3 billion by 2017. The market will be driven by the launch of promising Phase III molecules in cervical cancer, lung cancer, pancreatic cancer and melanoma. With patent-protection granted to available vaccines, the market will demonstrate significant growth. Strategic consolidations through M&A, deals and co-developments will provide R&D, marketing, sales and regulatory support in the future and help gain a greater market share.

Scope

- The report provides a market characterization, pipeline analysis and key M&A trends in the cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma vaccines market.
- Descriptive case studies, advantages and disadvantages for various types of cancer vaccine development and vaccine delivery methods
- Data and analysis on the emerging cancer vaccines market
- Annualized market data for the cancer vaccines market, with forecasts to 2017
- Market data on the therapeutic landscape which covers cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma, including market size, market share and annual cost of vaccination
- Key drivers and restraints that have had a significant impact on the market and on each indication
- The competitive landscape of the emerging cancer vaccines market which includes companies such as Merck, Amgen, GlaxoSmithKline, Dendreon
- Key M&A, deals and co-developments that took place from 2004 to 2011 in the global cancer vaccines market

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -
- Familiarize yourself with the different types of cancer vaccine development and vaccine delivery methods available, with case studies and analysis of advantages and disadvantages for a better understanding of the market.
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Devise a more tailored country strategy through the understanding of key drivers and barriers of each regions cancer vaccines market.
- Develop key strategic initiatives by understanding the key focus areas and top selling vaccines of leading companies.
- Accelerate and strengthen your market position by identifying key companies

  
Source:
Document ID
GBIHC124MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents37
  List of Tables62
  List of Figures82
Emerging Cancer Vaccines Market to 2017: Introduction102
  GBI Research Report Guidance102
Emerging Cancer Vaccines Market to 2017: Cancer Vaccine Development126
  Different Approaches to Cancer Vaccine Development121
    Whole-Cell Cancer Vaccines121
      Overview121
      Case Study: Provenge, Dendreon Corporation121
    Antigen Vaccines121
      Overview121
      Case Study: GV1001, KAEL-Gemvax131
    DNA Vaccines131
      Overview131
      Case Study: VGX-3100, Inovio Pharmaceuticals131
    Vector-based Vaccines131
      Overview131
      Case Study: Prostvac, Bavarian Nordic131
    Dendritic Cell (DC) Vaccines141
      Overview141
      Case Study: Provenge, Dendreon Corporation141
    Idiotype Vaccines141
      Overview141
      Case Study: BiovaxID, BioVest International141
  Cancer Vaccines in Combination Therapy (Adjuvants)151
    Microbes151
      Overview151
      Case Study: BCG Vaccine for Prostate Cancer151
    Substances Produced by Bacteria151
      Overview151
      Case Study: Melacine for Melanoma161
    Biological Products Derived from Non-Microbial Organisms161
      Overview161
      Case Study: BiovaxID for NHL161
    Non-Biological Substances161
      Overview161
      Case Study: NY-ESO-1b Peptide and Montanide ISA-51 Vaccine for Advanced Epithelial Ovarian Cancer161
    Natural or Synthetic Cytokines171
      Overview171
      Case Study: OncoVEXGM-CSF for Metastatic Melanoma171
Emerging Cancer Vaccines Market to 2017: Physical Delivery Methods183
  Introduction181
    Tattooing181
      Overview181
      Case Study: Peptide Vaccine Delivery by Tattooing and Subcutaneous Injection181
    Gene Gun191
      Overview191
      Case Study: pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccination by Gene Gun, Biojector, and Syringe191
    Ultrasound191
      Overview191
      Case Study: DNA-hsp65 Vaccine for Unresectable Squamous Cell Carcinoma of the Head and Neck191
    Electroporation201
      Overview201
      Case Study: VGX-3100 for CIN201
    Laser201
      Overview201
      Case Study: Femtosecond Laser Delivery201
Emerging Cancer Vaccines Market to 2017: Non-Physical Delivery Methods214
  Biological Gene Delivery Systems (Viral Vectors)211
    Overview211
    Case Study: Prostvac for Advanced Prostate Cancer211
  Non-Biological Gene Delivery Systems (Non-Viral Vectors)211
    Cationic Lipids/Liposomes211
      Overview211
      Case Study: Stimuvax for Unresectable, stage III Non-Small Cell Lung Cancer (NSCLC)221
    Polysaccharides and Cationic Polymers221
      Overview221
      Case Study: Herceptin-Conjugated Gemcitabine-Loaded Chitosan NPs for Pancreatic Cancer221
    Micro/Nano-particles221
      Overview221
      Case Study: Paclitaxel-Loaded PLGA NPs with Wheat Germ Agglutinin (WGA)231
    Cationic Peptides/CPP231
      Overview231
      Case Study: TAT-PEG-PEI Conjugate for Lung Cancer231
    Virus-Like Particles (VLPs) as an Efficient Delivery System231
      Overview231
      Case Study: V503 for Cervical Cancer231
    Delivery Systems in DC Vaccines241
    Delivery Systems in Protein/Peptide Vaccines241
    Mucosal Delivery System241
      Overview241
      Case Study: L. plantarum Expressing Oncofetal Antigen (OFA) for Mucosal Cancer Vaccine Delivery241
Emerging Cancer Vaccines Market to 2017: Market Overview256
  Introduction251
  Revenue252
  Annual Cost of Vaccination271
  Target Population281
    Coverage Population281
  Unmet Needs291
  Drivers and Restraints291
    Drivers291
    Restraints292
Emerging Cancer Vaccines Market to 2017: Therapeutic Landscape3127
  Cervical Cancer Vaccines Market311
    Introduction311
    Unmet Needs311
    Revenue321
    Annual Cost of Vaccination331
    Target Population341
      Coverage Population342
    Geographical Segmentation361
    Drivers and Restraints for the Cervical Cancer Vaccines Market371
      Drivers371
      Restraints371
  Prostate Cancer Vaccine Market371
    Introduction371
    Unmet Needs371
    Revenue381
    Annual Cost of Vaccination391
    Target Population401
      Coverage Population401
    Geographical Segmentation411
    Drivers and Restraints for the Prostate Cancer Vaccines Market421
      Drivers421
      Restraints421
  Lung Cancer Vaccines Market421
    Introduction421
    Unmet Needs421
    Revenue431
    Annual Cost of Vaccination441
    Target Population451
      Coverage Population451
    Geographical Segmentation461
    Drivers and Restraints for the Lung Cancer Vaccines Market471
      Drivers471
      Restraints471
  Pancreatic Cancer Vaccines Market471
    Introduction471
    Unmet Needs471
    Revenue481
    Annual Cost of Vaccination491
    Target Population501
      Coverage Population501
    Geographical Segmentation511
    Drivers and Restraints for the Pancreatic Cancer Vaccines Market521
      Drivers521
      Restraints521
  Melanoma Vaccines Market521
    Introduction521
    Unmet Needs521
    Revenue531
    Annual Cost of Vaccination541
    Target Population551
      Coverage Population551
    Geographical Segmentation561
    Drivers and Restraints for the Melanoma Vaccines Market571
      Drivers571
      Restraints571
Emerging Cancer Vaccines Market to 2017: Geographical Landscape5812
  The US581
    Revenue582
    Annual Cost of Vaccination601
    Target Population611
      Coverage Population612
  Top Five Countries in Europe631
    Revenue631
    Annual Cost of Vaccination641
    Target Population651
      Coverage Population652
  Japan671
    Revenue671
    Annual Cost of Vaccination681
    Target Population691
      Coverage Population691
Emerging Cancer Vaccines Market to 2017: Pipeline Analysis7040
  Introduction702
    Research and Development Pipeline Prostate Cancer Vaccines726
    Research and Development Pipeline Lung Cancer Vaccines786
    Research and Development Pipeline Pancreatic Cancer Vaccines845
    Research and Development Pipeline Melanoma Vaccines8913
    Research and Development Pipeline Cervical Cancer Vaccines1023
  R&D Trends1051
  Profiles of Promising Drugs in the Emerging Cancer Vaccines Market to 20171051
    Stimuvax1051
      Overview1051
      Efficacy1051
      Safety1051
      Clinical Study Details1051
    OncoVEXGM-CSF1061
      Overview1061
      Efficacy1061
      Safety1061
      Clinical Study Details1061
    V5031061
      Overview1061
      Efficacy1061
      Safety1061
      Clinical Study Details1071
    GV10011071
      Overview1071
      Efficacy1071
      Safety1071
      Clinical Study Details1071
    Lucanix1081
      Overview1081
      Efficacy1081
      Safety1081
      Clinical Study Details1081
    TG40101081
      Overview1081
      Efficacy1091
      Safety1091
      Clinical Study Details1091
Emerging Cancer Vaccines Market to 2017: Competitive Landscape11011
  Marketed Cancer Vaccines1101
    Gardasil1101
      Overview1101
      Efficacy1101
      Safety1101
      Clinical Study Details1101
    Cervarix1101
      Overview1101
      Efficacy1101
      Safety1111
      Clinical Study Details1111
    Provenge1111
      Overview1111
      Efficacy1111
      Safety1111
      Clinical Study Details1111
  Market Share Analysis1121
  Competitive Profiling1131
    Merck &Co., Inc.1131
      Business Description1131
      Product Portfolio1131
      Pipeline Portfolio1131
      SWOT Analysis1141
    Merck Serono1151
      Business Description1151
      Pipeline Portfolio1151
      SWOT Analysis1151
    Amgen1161
      Business Description1161
      Pipeline Portfolio1161
      SWOT Analysis1161
    GlaxoSmithKline1171
      Business Description1171
      Product Portfolio1171
      Pipeline Portfolio1171
      SWOT Analysis1181
    Dendreon1191
      Business Description1191
      Product Portfolio1191
      Pipeline Portfolio1191
      SWOT Analysis1201
    KAEL-Gemvax1201
      Business Description1201
      Pipeline Portfolio1201
Emerging Cancer Vaccines Market to 2017: Strategic Consolidations12124

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market" Oct 15, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Cancer-Vaccines-Market-to-2017-Novel-First-In-Class-Vaccines-in-Phase-II-and-Phase-III-Pipeline-to-Shape-the-Future-Cancer-Vaccines-Market-2115-284>
  
APA:
GBI Research Reports. (2011). Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market Oct 15, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Cancer-Vaccines-Market-to-2017-Novel-First-In-Class-Vaccines-in-Phase-II-and-Phase-III-Pipeline-to-Shape-the-Future-Cancer-Vaccines-Market-2115-284>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.